Lei Cui

Lei Cui has a wealth of experience in the field of cancer therapy. In 2009, they were a Research Student at Concordia University. From 2010 to 2016, they were a Postdoctoral Research Fellow and PhD Candidate at the University of Toronto. Her thesis title was "Optimization of Gold Nanoparticle Radiosensitizers for Cancer Therapy" and they achieved several research awards, 4 peer-reviewed papers, and 6 peer-reviewed abstracts. From 2016 to 2019, they were a Postdoctoral Research Fellow at Trillium Therapeutics Inc., where they designed and executed in vitro and in vivo studies to develop novel cancer therapy strategies. From 2019 to 2022, they were a Senior Scientist I and Scientist II at Constellation Pharmaceuticals, where they designed and executed PK/PD studies to assess the biodistribution of TREX1 inhibitors in tumor-bearing mouse models, as well as developed and optimized cancer and immune cells-based assays for compounds (TREX1 inhibitors) screening. Currently, they are a Principal Scientist at Ensem Therapeutics.

Lei Cui obtained a Bachelor of Science (B.Sc.) in Biochemistry from Concordia University between 2006 and 2009. Lei then went on to pursue a PhD in Pharmaceutical Sciences at the University of Toronto, which they completed in 2016. During their time at the University of Toronto, they also obtained certifications in Animal Handling and Surgery, Biosafety, and Clinical Radiobiology.